Journal profile · Rheumatology
Current Opinion in Rheumatology
ISSN 1040-8711 · eISSN 1531-6963 · Lippincott Williams and Wilkins Ltd. · UNITED STATES · Bimonthly
Current Opinion in Rheumatology: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 5.39; JCR Q1 (journal website); hybrid open access; review 6–12 weeks (community reports); community-reported acceptance: moderate; 59 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Opinion in Rheumatology is published by Lippincott Williams and Wilkins Ltd. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research and Spondyloarthritis Studies and Treatments, together about 37.1% of its articles. Its main subfields are Rheumatology. (generated from OpenAlex topic counts and CAS ranking data)
A high impact review journal which boasts an international readership, Current Opinion in Rheumatology offers a broad-based perspective on the most recent and exciting developments within the field of rheumatology. Published bimonthly, each issue features insightful editorials and high quality invited reviews covering two or three key disciplines which include vasculitis syndromes, medical physiology and rheumatic diseases, crystal deposition diseases and rheumatoid arthritis. Each discipline introduces world renowned guest editors to ensure the journal is at the forefront of knowledge development and delivers balanced, expert assessments of advances from the previous year.
Source: LetPub
Research area (LetPub): Rheumatology
Editor-in-chief John VargaPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Rheumatoid Arthritis Research and TherapiesMedicine17.1%
- Systemic Lupus Erythematosus ResearchMedicine11%
- Spondyloarthritis Studies and TreatmentsMedicine9%
- Systemic Sclerosis and Related DiseasesMedicine8.1%
- Inflammatory Myopathies and DermatomyositisMedicine7.3%
- Autoimmune and Inflammatory Disorders ResearchMedicine6.2%
- Vasculitis and related conditionsMedicine5.2%
- Osteoarthritis Treatment and MechanismsMedicine3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Rheumatology | Zone 3 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Rheumatology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Rheumatology | Zone 3 |
Top journal: noReview journal: yes
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · RHEUMATOLOGY · rank 7/58
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.39LetPub ·
- Impact factor (publisher)
- 5.4Publisher website ·
- CiteScore 2026-06
- 8.7LetPub ·
- SJR 2026-06
- 1.57LetPub ·
- SNIP 2026-06
- 1.52LetPub ·
- h-index
- 102LetPub ·
- h-index
- 156OpenAlex ·
- i10-index
- 2,439OpenAlex ·
- 2-year mean citedness
- 3.9OpenAlex ·
- Self-citation rate
- 1.9%LetPub ·
- Share of gold OA articles
- 9.36%LetPub ·
Volume
- Articles per year
- 53LetPub ·
Articles by year OpenAlex count · 3,804 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 49 | 12 | 10 |
| 2025 | 59 | 17 | 144 |
| 2024 | 71 | 20 | 544 |
| 2023 | 66 | 19 | 746 |
| 2022 | 56 | 16 | 1,335 |
| 2021 | 77 | 26 | 1,919 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lippincott Williams and Wilkins Ltd.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- ISSN
- 1040-8711
- Electronic ISSN
- 1531-6963
- Latest issue on the website
- Volume 38, Issue 5 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Opinion in Rheumatology
What CAS zone is Current Opinion in Rheumatology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Opinion in Rheumatology is in Zone 2 of Medicine, and in Zone 3 of the minor category Rheumatology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Opinion in Rheumatology?
The latest impact factor listed by LetPub is 5.39; CiteScore 8.7, h-index 156.
How long does peer review take at Current Opinion in Rheumatology?
Authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Current Opinion in Rheumatology in?
The journal's website gives JCR Q1; by category, RHEUMATOLOGY Q1 (7/58). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 2 of Medicine.
Which databases index Current Opinion in Rheumatology?
According to LetPub and DOAJ records, Current Opinion in Rheumatology is indexed in SCIE and Scopus.
Is Current Opinion in Rheumatology open access, and what is the APC?
Current Opinion in Rheumatology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .